Stifel lowered the firm’s price target on X4 Pharmaceuticals (XFOR) to $7.50 from $9 and keeps a Buy rating on the shares. The firm updated the company’s model post the earnings report and corporate update. The reduced target reflects revised financing assumptions, including the impact of X4’s October financing, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XFOR: